Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aarti DrugsNSE:AARTIDRUGS +1.36%74 EV-to-EBIT is 17.12 as of Sep. 07, 2026, which is 14% above its 10-year median of 15.07. GuruFocus rates NSE:AARTIDRUGS with a GF Score™ of 74/100 and a GF Value™ of ₹520.37 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Aarti Drugs ranks worse than 52.28% on this metric.
The historical rank and industry rank for Aarti Drugs's EV-to-EBIT or its related term are showing as below:
NSE:AARTIDRUGS'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.73 Med: 15.07 Max: 27.37
Current: 17.12
During the past 13 years, the highest EV-to-EBIT of Aarti Drugs was 27.37. The lowest was 5.73. And the median was 15.07.
NSE:AARTIDRUGS's EV-to-EBIT is ranked worse than 52.28% of 681
companies
in the Drug Manufacturers industry
Industry Median: 15.89
vs NSE:AARTIDRUGS: 17.12
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Aarti Drugs's Enterprise Value for the quarter that ended in Jun. 2026 was ₹34,491 Mil.
Aarti Drugs's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,634 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Drugs EV-to-EBIT Related Terms
Aarti Drugs EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Aarti Drugs's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Drugs EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Aarti Drugs's EV-to-EBIT falls into.
Aarti Drugs's current Enterprise Value is ₹45,090 Mil.
Aarti Drugs's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,634 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Drugs (NSE:AARTIDRUGS) has a EV-to-EBIT of 17.12 as of Sep. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aarti Drugs and its competitors. This is 14% above median its historical median of 15.07. Over the past decade, Aarti Drugs' EV-to-EBIT has ranged from 5.73 to 27.37. According to the industry distribution chart, Aarti Drugs ranks #356 out of 681 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Aarti Drugs' EV-to-EBIT too high?
Aarti Drugs' current EV-to-EBIT of 17.12 is 14% above median its 10-year median of 15.07. Over the past 10 years, this metric has ranged from a low of 5.73 to a high of 27.37. The Drug Manufacturers industry median EV-to-EBIT is 15.89. Aarti Drugs' value of 17.12 is 7.7% above this industry median. Based on the distribution chart, Aarti Drugs ranks #356 out of 681 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aarti Drugs has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Drugs' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarti Drugs ranks #356 out of 681 companies for EV-to-EBIT. This places Aarti Drugs in the lower half of its industry. The industry median EV-to-EBIT is 15.89. Aarti Drugs' value of 17.12 is 7.7% above this benchmark. Historically, Aarti Drugs' own EV-to-EBIT has ranged from 5.73 to 27.37 over the past decade. While the company's 10-year median is 15.07 vs. the industry median of 15.89, Aarti Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.89, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Drugs's current EV-to-EBIT of 17.12 is 7.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aarti Drugs and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Drugs's current EV-to-EBIT is 17.12, which is 14% above median its own 10-year median of 15.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Drugs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Drugs (NSE:AARTIDRUGS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹520.37, compared to a current price of ₹431.65 — trading 17% below its estimated fair value. The current EV-to-EBIT is 17.12, which is 14% above median its 10-year median of 15.07 and 7.7% above the Drug Manufacturers industry median of 15.89. Aarti Drugs' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Aarti Drugs (NSE:AARTIDRUGS), the current EV-to-EBIT is 17.12 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued.
The current stock price of ₹431.65 is trading 17% below its estimated GF Value™ of ₹520.37.
GuruFocus considers Aarti Drugs to be Modestly Undervalued.
Key valuation signals for NSE:AARTIDRUGS:
EV-to-EBIT: 17.12 (14% above median its 10-year median of 15.07)
GF Value™: ₹520.37 vs. price of ₹431.65 (17% below fair value)
Industry Position: 7.7% above the Drug Manufacturers median (#356 of 681)
No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
74GF Score
Get the complete analysis for NSE:AARTIDRUGS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIDRUGS has been successfully added to your 
